Overview
The SURMOUNT program tested weekly tirzepatide in adults with obesity or overweight, together with diet and exercise. Most trials compared tirzepatide with placebo over 72 weeks. A sister program, SURPASS, studied tirzepatide in type 2 diabetes and led to the approval of Mounjaro.
Main trials
SURMOUNT-1 was the main trial in adults without diabetes. People on the 15 mg dose lost 20.9% of their body weight on average after 72 weeks, compared with 3.1% on placebo. About 56.7% of people on that dose lost at least 20% of their weight.
In SURMOUNT-2, adults with obesity and type 2 diabetes lost 12.8% (10 mg) and 14.7% (15 mg) of their body weight on tirzepatide after 72 weeks, vs. 3.2% on placebo.
SURMOUNT-3 gave tirzepatide to people who had first lost weight through an intensive lifestyle program.
Stopping treatment
SURMOUNT-4 tested what happens when tirzepatide is stopped after people have lost weight. In SURMOUNT-4, people who stayed on tirzepatide after a 36-week lead-in lost another 5.5% of their weight over the next 52 weeks, while people switched to placebo regained 14.0%. The authors concluded that stopping tirzepatide led to a large regain of lost weight.
Head-to-head and sleep apnea trials
SURMOUNT-5 was the first trial to compare tirzepatide directly with semaglutide for weight loss, in adults without diabetes. In the one head-to-head trial, SURMOUNT-5, people on tirzepatide lost 20.2% and people on semaglutide lost 13.7% after 72 weeks (treatment-regimen estimand).
SURMOUNT-OSA was 2 trials in adults with obesity and moderate to severe obstructive sleep apnea, one in people not using a breathing machine and one in people using it. In SURMOUNT-OSA, the number of breathing pauses per hour of sleep (apnea-hypopnea index) fell by about 25 to 29 events on tirzepatide after 52 weeks, vs. about 5 events on placebo. These results led to the December 20, 2024, sleep apnea approval for Zepbound.
Our semaglutide vs. tirzepatide page compares the two medicines in more detail.
Compare semaglutide and tirzepatide
See also
References
- Jastreboff et al., NEJM 2022;387:205-216 (SURMOUNT-1). pubmed.ncbi.nlm.nih.gov
- Garvey et al., Lancet 2023;402:613-626 (SURMOUNT-2). pubmed.ncbi.nlm.nih.gov
- Wadden et al., Nat Med 2023;29:2909-2918 (SURMOUNT-3). pubmed.ncbi.nlm.nih.gov
- Aronne et al., JAMA 2024;331:38-48 (SURMOUNT-4). pubmed.ncbi.nlm.nih.gov
- Aronne et al., NEJM 2025;393:26-36 (SURMOUNT-5). pubmed.ncbi.nlm.nih.gov
- Malhotra et al., NEJM 2024;391:1193-1205 (SURMOUNT-OSA). pubmed.ncbi.nlm.nih.gov
Last updated . Category: Concepts. Browse all 38 WikiTelehealth entries.